Document is current
Any future updates will be listed below
-
Authors
Yen, Ivana
Shanahan, Frances
Lee, Jeeyun https://orcid.org/0000-0002-4911-6165
Hong, Yong Sang
Shin, Sang Joon
Moore, Amanda R. https://orcid.org/0000-0003-3864-6387
Sudhamsu, Jawahar https://orcid.org/0000-0003-0737-2299
Chang, Matthew T.
Bae, Inhwan https://orcid.org/0000-0001-5390-2401
Dela Cruz, Darlene
Hunsaker, Thomas
Klijn, Christiaan
Liau, Nicholas P. D. https://orcid.org/0000-0002-3887-899X
Lin, Eva
Martin, Scott E.
Modrusan, Zora
Piskol, Robert https://orcid.org/0000-0001-8942-9943
Segal, Ehud
Venkatanarayan, Avinashnarayan
Ye, Xin
Yin, Jianping
Zhang, Liangxuan
Kim, Jin-Soo
Lim, Hyeong-Seok
Kim, Kyu-Pyo
Kim, Yu Jung
Han, Hye Sook
Lee, Soo Jung
Kim, Seung Tae
Jung, Minkyu
Hong, Yoon-hee https://orcid.org/0000-0002-8224-4396
Noh, Young Su https://orcid.org/0000-0002-4204-2503
Choi, Munjeong
Han, Oakpil
Nowicka, Malgorzata
Srinivasan, Shrividhya
Yan, Yibing
Kim, Tae Won https://orcid.org/0000-0001-9522-1997
Malek, Shiva https://orcid.org/0000-0002-9526-7968
- License Information
-
More Information
Article History
Received: 16 August 2020
Accepted: 5 April 2021
First Online: 5 May 2021
Competing interests
: Hanmi Pharmaceutical Co., Ltd. funded the clinical study and assisted in preparation of the manuscript. S.M., I.Y. and Y.Y. are employees and stockholders of Genentech/Roche, and inventors of the patent application on belvarafenib. F.S., A.R.M., A.V., C.K., J.Y., N.P.D.L., E.L., L.Z., X.Y., E.S., D.D.C., T.H., Z.M., S.E.M., J.S., M.T.C., R.P., M.N. and S.S. are employees and stockholders of Genentech/Roche. T.W.K. is an inventor of the patent application on belvarafenib and received research funding from Sanofi-Aventis. J.L. is a consultant for Oncologie and Seattle Genetics and received research funding from AstraZeneca, Merck Sharp & Dohme, and Lilly. J.-S.K. is a stockholder of Dae Hwa Pharmaceutical and a consultant for Lilly and CJ Healthcare, provided expert testimony for CJ Healthcare, received honoraria from Merck, CJ Healthcare, Lilly, Boehringer Ingelheim, AstraZeneca, and Dae Hwa Pharmaceutical, and received research funding from AstraZeneca, Boehringer Ingelheim, Sanofi, Lilly, CJ Healthcare, Hanmi Pharmaceutical, Chong Kun Dang Pharmaceutical, Ono Pharmaceutical, Pfizer, Novotech, Astellas Pharma, Merck, Aslan Pharmaceuticals, Alphabiopharma, Yuhan, MSD, and Il-Yang Pharmiceutical. Y.-H.H. and Y.S.N. are employees of Hanmi Pharmaceutical and inventors of the patent application on belvarafenib. M.C. and O.H. are employees of Hanmi Pharmaceutical. The remaining authors have no conflicts of interest to disclose.
